“VYGR had a 6/30 cash balance of $141MM, sufficient to fund operations into 2019.”,” the firm’s analyst wrote.
Several other equities analysts also recently issued reports on the stock. Stifel Nicolaus began coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They issued a buy rating and a $20.00 price objective for the company. ValuEngine downgraded shares of Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Friday, July 28th. BidaskClub upgraded shares of Voyager Therapeutics from a strong sell rating to a sell rating in a research note on Thursday, July 13th. Zacks Investment Research downgraded shares of Voyager Therapeutics from a hold rating to a sell rating in a research note on Thursday, July 13th. Finally, Wedbush reiterated an outperform rating and set a $36.00 target price on shares of Voyager Therapeutics in a research note on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. Voyager Therapeutics currently has an average rating of Hold and a consensus target price of $23.43.
Shares of Voyager Therapeutics (NASDAQ VYGR) traded down 0.35% during trading on Tuesday, reaching $8.54. The company’s stock had a trading volume of 65,196 shares. The stock’s market cap is $229.75 million. The company has a 50 day moving average of $9.08 and a 200-day moving average of $10.50. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $18.25.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.11. Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $3.27 million. Analysts forecast that Voyager Therapeutics will post ($2.84) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Voyager Therapeutics, Inc. (VYGR) Given Buy Rating at Cowen and Company” was originally reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/voyager-therapeutics-vygr-buy-rating-reaffirmed-at-cowen-and-company-updated.html.
A number of hedge funds and other institutional investors have recently modified their holdings of VYGR. Vanguard Group Inc. boosted its position in shares of Voyager Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after buying an additional 13,194 shares during the period. DAFNA Capital Management LLC boosted its position in shares of Voyager Therapeutics by 187.2% in the second quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after buying an additional 133,488 shares during the period. State Street Corp boosted its position in shares of Voyager Therapeutics by 11.8% in the second quarter. State Street Corp now owns 184,526 shares of the company’s stock worth $1,653,000 after buying an additional 19,471 shares during the period. Northern Trust Corp boosted its position in shares of Voyager Therapeutics by 26.8% in the second quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after buying an additional 28,222 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock worth $1,739,000 after buying an additional 19,450 shares during the period. 41.36% of the stock is owned by institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.